You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go Back

According to CDC, 76% of pertussis-related deaths occur in infants aged under 2 months 1


  • Infants do not begin their own primary vaccine series against pertussis (with the diphtheria, tetanus toxoids and pertussis) until approximately 2 months of age, 5 leaving them unprotected during the highly vulnerable newborn period 23
  • Pertussis disease can occur in all age groups, but can cause serious and life-threatening complications in unvaccinated, vulnerable newborns and young infants 45
  • Infants under 2 months of age account for most severe pertussis cases, hospitalizations, and deaths due to pertussis 56

Newborns and young infants are at highest risk of fatal outcome from pertussis 78


  1. The National Vaccine Advisory Committee: reducing patient and provider barriers to maternal immunizations: approved by the National Advisory Committee on June 11, 2014. Public Health Rep. 2015;130:10-42. [accessed February 2018]; Available at:
  2. CDC Recommended immunization for children. Updated Dec 2016. [accessed March 2018]; Available at:
  3. ACOG Committee Opinion. Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Number 718, September 2017. [accessed March 2018]; Available at:
  4. Centers for Disease Control (CDC). Pertussis (Whooping Cough). [accessed March 2018]; Available at:
  5. Tiwari TS, et al. First pertussis vaccine dose and prevention of infant mortality. Pediatrics. 2015;135:990-999.
  6. Gkentzi D, et al. Maternal vaccination against pertussis: a systematic review of the recent literature. Arch Dis Child Fetal Neonatal Ed. 2017;102:F456-F463.
  7. Hong JY. Update on pertussis and pertussis immunization. Korean J Pediatr. 2010;53:629-633.
  8. Healy CM. Pertussis vaccination in pregnancy. Hum Vaccin Immunother. 2016;12(8):1972-1981.

For the use of Registered Medical Practioners.
Please report any adverse event with any GSK produsts to the company at